Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARS-2 in Chronic Spontaneous Urticaria
2025-521930-27-00Phase 2Authorised
- Sponsor
- ARS Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of epinephrine in chronic idiopathic urticaria (CIU) (2 arms), sponsored by ARS Pharmaceuticals. Primary endpoints: Change in itch score (UAS) and Change in hive score (UAS). Planned start Aug 2025; status: authorised.
02
Drugs
epinephrine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2025-521930-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521930-27-00.